URBAN, MARIA LETIZIA
 Distribuzione geografica
Continente #
NA - Nord America 1.687
EU - Europa 1.231
AS - Asia 307
AF - Africa 3
SA - Sud America 1
Totale 3.229
Nazione #
US - Stati Uniti d'America 1.687
IT - Italia 328
IE - Irlanda 266
SE - Svezia 199
PL - Polonia 193
HK - Hong Kong 121
RU - Federazione Russa 86
CN - Cina 64
SG - Singapore 48
CH - Svizzera 41
DE - Germania 38
JO - Giordania 35
GB - Regno Unito 24
IQ - Iraq 13
ES - Italia 12
BE - Belgio 11
UA - Ucraina 9
VN - Vietnam 9
AT - Austria 8
IN - India 6
FI - Finlandia 5
FR - Francia 5
IR - Iran 5
JP - Giappone 3
GR - Grecia 2
KR - Corea 2
MK - Macedonia 2
NG - Nigeria 2
NL - Olanda 2
BR - Brasile 1
IL - Israele 1
MU - Mauritius 1
Totale 3.229
Città #
Dublin 266
Fairfield 233
Chandler 192
Warsaw 192
Ashburn 143
Woodbridge 100
Seattle 98
Houston 93
Lawrence 80
Altamura 76
Cambridge 73
Wilmington 71
Ann Arbor 68
Hong Kong 68
Moscow 60
Florence 54
Princeton 54
Boston 50
Buffalo 44
Bern 41
New York 28
Beijing 27
Singapore 27
San Diego 25
Shanghai 20
Boardman 18
Medford 18
Baghdad 13
Kent 13
Milan 13
Rome 13
Brussels 11
Falls Church 11
Dong Ket 8
Guangzhou 8
London 8
Norwalk 8
Vienna 8
Andover 7
Cagliari 7
Hillsboro 7
Arezzo 6
Pamplona 6
Redwood City 6
Rolla 6
Bologna 5
Napoli 5
Washington 5
Barcelona 4
Campi Bisenzio 4
Castelliri 4
Laurel 4
Mumbai 4
West Jordan 4
Bari 3
Lappeenranta 3
Los Angeles 3
Menlo Park 3
Padova 3
Parma 3
Saint Petersburg 3
Sesto Fiorentino 3
Acton 2
Cinisello Balsamo 2
Genoa 2
Kilburn 2
Lagos 2
Montalcino 2
Paris 2
Piombino 2
Poggio Rusco 2
Prato 2
Romainville 2
San Venanzo 2
Seoul 2
Taiyuan 2
Tokyo 2
Treviso 2
Valencia 2
Venice 2
Virle Piemonte 2
Amsterdam 1
Anguillara Sabazia 1
Barlassina 1
Busto Arsizio 1
Canosa di Puglia 1
Cedar Knolls 1
Chicago 1
Duisburg 1
Düsseldorf 1
Frankfurt am Main 1
Grossmuehlingen 1
Gunzenhausen 1
Hangzhou 1
Hanover 1
Helsinki 1
Ho Chi Minh City 1
Hounslow 1
Jacksonville 1
Landshut 1
Totale 2.498
Nome #
Repeated low-dose courses of rituximab in SLE-associated antiphospholipid syndrome: Data from a tertiary dedicated centre 205
Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet’s syndrome 105
A large-scale genetic analysis reveals an autoimmune origin of idiopathic retroperitoneal fibrosis 93
Intravenous immunoglobulin for the secondary prevention of stillbirth in obstetric antiphospholipid syndrome: A case series and systematic review of literature 93
Brief Report: Rituximab for the treatment of adult-onset IgA vasculitis (Henoch-Schönlein purpura) 85
Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with outcomes among patients with ANCA-associated renal vasculitis 82
Secukinumab reduces plasma oxidative stress in psoriasis: A case-based experience 80
Cutaneous sarcoidosis during rituximab treatment for microscopic polyangiitis: An uncommon adverse effect? 75
Cardiac involvement in eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome): Prospective evaluation at a tertiary referral centre 73
OP0148 MEPOLIZUMAB FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A RETROSPECTIVE REAL-WORLD EUROPEAN STUDY ON 142 PATIENTS 72
Significance of PR3-ANCA Positivity in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss) 69
Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis 69
Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet's phenotype: A multicentre study 68
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting 62
Asbestos and Smoking as Risk Factors for Idiopathic Retroperitoneal Fibrosis 61
Unveiling the efficacy, safety, and tolerability of anti-interleukin-1 treatment in monogenic and multifactorial autoinflammatory diseases 59
New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA): report of the first meeting of the European EGPA Study Group 58
A unique circulating miRNA profile highlights thrombo-inflammation in Behçet's syndrome 58
Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome) 57
Clinical and Prognostic Significance of Serum IgG4 in Chronic Periaortitis. An Analysis of 113 Patients 56
Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis 55
Obstetric antiphospholipid syndrome is not associated with an increased risk of subclinical atherosclerosis 55
Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes 55
Comparison of treatments for the prevention of fetal growth restriction in obstetric antiphospholipid syndrome: a systematic review and network meta-analysis 54
135. ATHERO-THROMBOTIC AND VENOUS EVENTS (AVTE) IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A MULTICENTRE STUDY OF 573 ITALIAN PATIENTS 53
Adalimumab effectiveness in Behçet’s disease: short and long-term data from a multicenter retrospective observational study 53
Rituximab for chronic periaortitis without evidence of IgG4-related disease: A long-term follow-up study of 20 patients 52
SARS-CoV-2 infection among patients with systemic autoimmune diseases 50
298. RITUXIMAB FOR DIFFICULT-TO-TREAT CHRONIC PARIAORTITIS: A CASE-SERIES OF 20 PATIENTS 50
Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study 48
Chronic periaortitis with thoracic aorta and epiaortic artery involvement: a systemic large vessel vasculitis? 47
Idiopathic Mediastinal Fibrosis: a Systemic Immune-Mediated Disorder. A Case Series and a Review of the Literature 47
Fcγ-receptor 3B (FCGR3B) copy number variations in patients with eosinophilic granulomatosis with polyangiitis 47
Neutrophil-mediated mechanisms of damage and in vitro protective effect of colchicine in non-vascular Behçet's syndrome 47
Association of a polymorphism of the Fcγ-receptor 2A (FCGR2A) gene with chronic periaortitis 44
Rituximab therapy for chronic periaortitis 43
Treatment of idiopathic retroperitoneal fibrosis 41
POS1212 SARS-CoV-2 INFECTION AMONG PATIENTS WITH BEHÇET’S SYNDROME 41
Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis 41
Fibrocytes in Chronic Periaortitis: A Novel Mechanism Linking Inflammation and Fibrosis 41
ModulAtion of gut Microbiota through nutritional interventions in Behçet's syndrome pAtients: the MAMBA Study 41
Evidence of subclinical atherosclerosis in Eosinophilic Granulomatosis with Polyangiitis (EGPA) 40
Pathophysiology of IgG4-related disease: A T follicular helper cells disease? 40
Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study 39
Pharmacological interventions for the prevention of fetal growth restriction: a systematic review and network meta-analysis 39
Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients 39
Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases 37
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort 37
Idiopathic and secondary forms of retroperitoneal fibrosis: A diagnostic approach 36
FCGR3B polymorphism predicts relapse risk in eosinophilic granulomatosis with polyangiitis 36
Slowly progressive ANCA-associated renal vasculitis. Clinico-pathological characterisation and outcome 35
Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis with Polyangiitis: data from a European Collaborative Study 34
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study-Joint and Skin (BeRLiSS-JS) 33
Prevalence and clinical course of SARS-CoV-2 infection in patients with Behçet's syndrome 33
Occupational Exposures and Smoking in Eosinophilic Granulomatosis With Polyangiitis: A Case–Control Study 32
Prevalence and clinical associations of ultrasound-confirmed enthesitis in systemic lupus erythematosus 28
Complement blockade in ANCA-associated vasculitis: an index case, current concepts and future perspectives 25
Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS) 23
The management of transitional care of patients affected by phenylketonuria in Italy: Review and expert opinion 19
Systemic Fibroinflammatory Disorders - Diffuse (Thoraco-Abdominal) Periaortitis 19
Persistent Isolated C3 Hypocomplementemia as a Strong Predictor of End-Stage Kidney Disease in Lupus Nephritis 15
Association between idiopathic retroperitoneal fibrosis and autoimmune thyroiditis: A case–control study 12
Dupilumab for relapsing or refractory sinonasal and/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective study 11
Validity of Machine Learning in Predicting Giant Cell Arteritis Flare After Glucocorticoids Tapering 11
Editorial: New insights into pathophysiology and management of pregnancy in systemic autoimmune diseases: Toward new therapeutic approaches 10
Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial 10
Validation of the Italian version of the ANCA-associated vasculitis patient-reported outcome (AAV-PRO) questionnaire 9
Disease activity at conception predicts lupus flare up to two years after birth: A multicentre long term follow-up study 9
Fc gamma-receptor 3B (FCGR3B) copy number variations in patients with eosinophilic granulomatosis with polyangiitis 8
Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study 6
Fibrosis - A Common Pathway to Organ Injury and Failure 6
SIRT1 and thrombosis 6
Evaluation of lupus anticoagulant, damage, and remission as predictors of pregnancy complications in systemic lupus erythematosus: the French GR2 study 5
Long-term outcome of a cohort of Italian patients affected with alpha-Mannosidosis 1
Totale 3.328
Categoria #
all - tutte 16.702
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.702


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020291 7 13 6 8 19 22 30 29 29 23 23 82
2020/2021529 14 73 17 39 55 51 40 54 52 57 37 40
2021/2022513 25 9 85 19 15 56 14 42 29 20 87 112
2022/20231.179 90 255 72 53 50 203 170 68 106 12 41 59
2023/2024619 13 39 74 40 48 78 35 113 20 80 38 41
2024/202576 76 0 0 0 0 0 0 0 0 0 0 0
Totale 3.328